Pediatric low-grade glioma in the era of molecular diagnostics
Low grade gliomas are the most frequent brain tumors in children and encompass a
spectrum of histologic entities which are currently assigned World Health Organisation …
spectrum of histologic entities which are currently assigned World Health Organisation …
Wild-type and mutated IDH1/2 enzymes and therapy responses
RJ Molenaar, JP Maciejewski, JW Wilmink… - Oncogene, 2018 - nature.com
Abstract Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism,
epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the …
epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the …
Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging
Purpose: Isocitrate dehydrogenase (IDH) mutations in glioma patients confer longer survival
and may guide treatment decision making. We aimed to predict the IDH status of gliomas …
and may guide treatment decision making. We aimed to predict the IDH status of gliomas …
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas
A Olar, KM Wani, KD Alfaro-Munoz, LE Heathcock… - Acta …, 2015 - Springer
Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate
that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of …
that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of …
Retracted: A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas
CG Bangalore Yogananda, BR Shah… - Neuro …, 2020 - academic.oup.com
Background. Isocitrate dehydrogenase (IDH) mutation status has emerged as an important
prognostic marker in gliomas. Currently, reliable IDH mutation determination requires …
prognostic marker in gliomas. Currently, reliable IDH mutation determination requires …
Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss
H Arita, Y Narita, S Fukushima, K Tateishi… - Acta …, 2013 - Springer
Telomere lengthening is one of the key events in most cancers, and depends largely on
telomerase activation. Telomerase activation is a well-known phenomenon in gliomas; …
telomerase activation. Telomerase activation is a well-known phenomenon in gliomas; …
The classification of gliomas based on a pyramid dilated convolution resnet model
Z Lu, Y Bai, Y Chen, C Su, S Lu, T Zhan, X Hong… - Pattern Recognition …, 2020 - Elsevier
Gliomas are characterized by high morbidity and high mortality in primary tumors. The
identification of glioma type is helpful for radiologists to facilitate correct medical judgments …
identification of glioma type is helpful for radiologists to facilitate correct medical judgments …
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key events in the
development of glioma, acute myeloid leukemia (AML), chondrosarcoma, intrahepatic …
development of glioma, acute myeloid leukemia (AML), chondrosarcoma, intrahepatic …
What do we know about IDH1/2 mutations so far, and how do we use it?
C Horbinski - Acta neuropathologica, 2013 - Springer
Whole genome analyses have facilitated the discovery of clinically relevant genetic
alterations in a variety of diseases, most notably cancer. A prominent example of this was …
alterations in a variety of diseases, most notably cancer. A prominent example of this was …
Isocitrate dehydrogenase (IDH) 1/2 mutations as prognostic markers in patients with glioblastomas
JR Chen, Y Yao, HZ Xu, ZY Qin - Medicine, 2016 - journals.lww.com
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Ma... : Medicine Isocitrate
Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas …
Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas …